In Vivo
>>Business Strategy

CEO Interview: Novartis' Dan Vasella

01 Apr 2007

Novartis has done better than most Pharmas over the past five years, though shareholders are still dissatisfied. But CEO Dan Vasella continues playing for the long-term -- pursuing R&D innovation and cost-effective dealmaking, all within a relatively conservative strategic framework.

By Roger Longman

All in all, it’s been a rough start to 2007 for Novartis AG’s flagship pharmaceutical division and the company’s chairman...